TABLE 4

Retention time, molecular ions, and characteristic fragment ions of dasabuvir and metabolites in human plasma, urine, or feces

Compound	Observed [M-H]⁻	Theoretical [M-H]⁻	Mass Error	Metabolite ID	CharacteristicFragment Ions^{^b}
			ppm
Dasabuvir	492.1601	492.1599	0.41	Parent drug	477^{^c} (−CH₃), 462 (−2 CH₃), 449 (−NCO), 435 (−C₄H₉), 414 (−SO₂CH₂), 399 (−SO₂CH₂ and −CH₃)
M1	508.1550	508.1548	0.39	P +O	493^{^c} (−CH₃), 476 (−CH₃OH), 463 (−C₂H₅O), 435 (−C₄H₉O), 430 (−SO₂CH₂), 415 (−SO₂CH₂ and −CH₃), 399 (−SO₂CH₂ and −CH₃O)
M2	588.1111	588.1116	−0.85	M1 sulfate	545 (−NCO), 509^{^c} (−CH₃SO₂), 494 (−CH₃SO₂ and −CH₃), 466 (−NCO and −CH₃SO₂), 465 (−NCO and −SO₃), 433 (−NCO and −CH₄SO₄)
M3	684.1861	684.1869	−1.17	M1 glucuronide	641 (−NCO), 597 (−NCO and −CO₂), 476^{^c} (−C₇H₁₂O₇), 433 (−C₇H₁₂O₇ and −NCO)
M4	506.1381	506.1391	−1.98	M1 −2H	463^{^c} (−C₂H₃O), 435 (−C₄H₇O), 413 (−SO₂CH₂ and −CH₃)
M5	522.1337	522.1340	−0.57	P +2O, −2H	507 (−CH₃), 478 (−CO₂), 463^{^c} (−C₂H₃O₂), 435 (−C₄H₇O₂)
M6	698.1657	698.1661	−0.57	M5 glucuronide	522 (−C₆H₈O₆), 478^{^c} (−C₆H₈O₆ and −CO₂), 463(−C₆H₈O₆, −CO₂, and −CH₃), 383 (−C₆H₈O₆, −CO₂, −CH₃, −CH₄SO₂)
M7	700.1801	700.1818	−2.43	M6 +2H	524^{^c} (−C₆H₈O₆), 444 (−C₆H₈O₆ and −CH₄SO₂)
M8^{^a}	524.1487	524.1497	−1.91	M5 +2H	480 (−CO₂), 465^{^c} (−C₂H₃O₂), 437 (−C₄H₇O₂), 401 (−CO₂ and −CH₃SO₂), 387 (−CO₂, −CH₂SO₂, and −CH₃)
M9^{^a}	510.1694	510.1704	−1.96	M1 +2H	495^{^c} (−CH₃), 478 (−CH₃OH), 465 (−C₂H₅O), 452, 437 (−C₄H₉O)
M10^{^a}	590.1260	590.1272	−2.03	M2 +2H	N/A
M11	494.1380	494.1391	−2.33	M1 –CH₂	479^{^c} (−CH₃), 464 (−2 CH₃), 416 (−SO₂CH₂), 401 (−SO₂CH₂ and −CH₃)

N/A, not available; P, parent drug.
↵^a Observed only in fecal samples.
↵^b Minus signs indicate loss.
↵^c base fragment ion.